208 related articles for article (PubMed ID: 37968716)
1. Measurement properties of the EQ-5D-5L and PROPr in patients with spinal muscular atrophy.
Xu RH; Ma B; Xin H; Zhang H; Zeng Y; Luo N; Dong D
Health Qual Life Outcomes; 2023 Nov; 21(1):123. PubMed ID: 37968716
[TBL] [Abstract][Full Text] [Related]
2. A Direct Comparison of the Measurement Properties of EQ-5D-5L, PROMIS-29+2 and PROMIS Global Health Instruments and EQ-5D-5L and PROPr Utilities in a General Population Sample.
Rencz F; Brodszky V; Janssen MF
Value Health; 2023 Jul; 26(7):1045-1056. PubMed ID: 36804583
[TBL] [Abstract][Full Text] [Related]
3. Assessing validity of the EQ-5D-5L proxy in children and adolescents with Duchenne muscular dystrophy or spinal muscular atrophy.
Xu RH; Dai Y; Ng SSM; Tsang HWH; Zhang S; Dong D
Eur J Health Econ; 2024 Feb; 25(1):103-115. PubMed ID: 36809586
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the PROMIS Preference Score (PROPr) and EQ-5D-5L Index Value in General Population Samples in the United Kingdom, France, and Germany.
Klapproth CP; Sidey-Gibbons CJ; Valderas JM; Rose M; Fischer F
Value Health; 2022 May; 25(5):824-834. PubMed ID: 35500951
[TBL] [Abstract][Full Text] [Related]
5. Understanding the measurement relationship between EQ-5D-5L, PROMIS-29 and PROPr.
Mulhern BJ; Pan T; Norman R; Tran-Duy A; Hanmer J; Viney R; Devlin NJ
Qual Life Res; 2023 Nov; 32(11):3147-3160. PubMed ID: 37347395
[TBL] [Abstract][Full Text] [Related]
6. Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary.
Nikl A; Janssen MF; Jenei B; Brodszky V; Rencz F
Pharmacoeconomics; 2024 May; 42(5):583-603. PubMed ID: 38416366
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of PROPr and EQ-5D-5L Value Sets.
Pan T; Mulhern B; Viney R; Norman R; Hanmer J; Devlin N
Pharmacoeconomics; 2022 Mar; 40(3):297-307. PubMed ID: 34786591
[TBL] [Abstract][Full Text] [Related]
8. Psychometric properties of the PROMIS Preference score (PROPr) in patients with rheumatological and psychosomatic conditions.
Klapproth CP; Fischer F; Merbach M; Rose M; Obbarius A
BMC Rheumatol; 2022 Mar; 6(1):15. PubMed ID: 35249554
[TBL] [Abstract][Full Text] [Related]
9. Scale agreement, ceiling and floor effects, construct validity, and relative efficiency of the PROPr and EQ-5D-3L in low back pain patients.
Klapproth CP; Fischer F; Rose M
Health Qual Life Outcomes; 2023 Sep; 21(1):107. PubMed ID: 37759272
[TBL] [Abstract][Full Text] [Related]
10. Cross-sectional validation of the PROMIS-Preference scoring system by its association with social determinants of health.
Hanmer J
Qual Life Res; 2021 Mar; 30(3):881-889. PubMed ID: 33161483
[TBL] [Abstract][Full Text] [Related]
11. Investigating the psychometric properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, CHU-9D, and PedsQL in children and adolescents with osteogenesis imperfecta.
Xu RH; Zhu L; Sun R; Tan RL; Luo N; Zou S; Dong D
Eur J Pediatr; 2022 Dec; 181(12):4049-4058. PubMed ID: 36156120
[TBL] [Abstract][Full Text] [Related]
12. Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form.
Lin FJ; Pickard AS; Krishnan JA; Joo MJ; Au DH; Carson SS; Gillespie S; Henderson AG; Lindenauer PK; McBurnie MA; Mularski RA; Naureckas ET; Vollmer WM; Lee TA;
BMC Med Res Methodol; 2014 Jun; 14():78. PubMed ID: 24934150
[TBL] [Abstract][Full Text] [Related]
13. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
[TBL] [Abstract][Full Text] [Related]
14. Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis.
Koszorú K; Hajdu K; Brodszky V; Bató A; Gergely LH; Kovács A; Beretzky Z; Sárdy M; Szegedi A; Rencz F
Eur J Health Econ; 2023 Feb; 24(1):139-152. PubMed ID: 35412162
[TBL] [Abstract][Full Text] [Related]
15. Validity and measurement equivalence of EQ-5D-5L questionnaire among heart failure patients in Malaysia: a cohort study.
Kuan WC; Chee KH; Kasim S; Lim KK; Dujaili JA; Lee KK; Teoh SL
J Med Econ; 2024; 27(1):607-617. PubMed ID: 38557412
[TBL] [Abstract][Full Text] [Related]
16. Psychometric performance of EQ-5D-5L and SF-6DV2 in measuring health status of populations in Chinese university staff and students.
Zhou HJ; Zhang A; Wei J; Wu J; Luo N; Wang P
BMC Public Health; 2023 Nov; 23(1):2314. PubMed ID: 37993793
[TBL] [Abstract][Full Text] [Related]
17. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey.
Xie S; Wang D; Wu J; Liu C; Jiang W
Health Qual Life Outcomes; 2022 Jun; 20(1):96. PubMed ID: 35710429
[TBL] [Abstract][Full Text] [Related]
19. Cross-sectional validation of the PROMIS-Preference scoring system.
Hanmer J; Dewitt B; Yu L; Tsevat J; Roberts M; Revicki D; Pilkonis PA; Hess R; Hays RD; Fischhoff B; Feeny D; Condon D; Cella D
PLoS One; 2018; 13(7):e0201093. PubMed ID: 30063733
[TBL] [Abstract][Full Text] [Related]
20. A head-to-head comparison of the EQ-5D-5L and 15D descriptive systems and index values in a general population sample.
Nikl A; Janssen MF; Brodszky V; Rencz F
Health Qual Life Outcomes; 2023 Feb; 21(1):17. PubMed ID: 36803866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
